Pharmacia & Upjohn Zyvox
Executive Summary
Preliminary Phase III data presented at ICAAC indicate Zyvox (linezolid) is effective for the treatment of infections caused by Gram-positive bacteria in adults and children. An interim analysis determined 66.4% of patients treated with I.V. Zyvox plus aztreonam demonstrated clinical success in the treatment of hospital acquired pneumonia compared to 68.1% treated with I.V. vancomycin plus aztreonam. Equivalence was also demonstrated in a Phase III trial assessing the efficacy of Zyvox vs. oral cefpodoxime in the treatment of community acquired pneumonia (89.6% vs. 90.8%). Zyvox was more efficacious in treating CAP than I.V. ceftriaxone followed by cefpodoxime (93.3% vs. 69.9%). In the treatment of complicated skin and soft tissue infections, Zyvox was 90.7% effective vs. 86.3% for the comparator (I.V. oxacillin/oral dicloxacillin) treated group. Nausea (5.4%), diarrhea (5.2%), tongue discoloration (2.5%) and oral monilia (2.3%) were the most frequently reported adverse events in a Phase II safety and tolerance study. P&U anticipates an NDA filing by the end of 1999
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth